Pernix Therapeutics Announces Omeclamox-Pak Available; Abbott Announces New Test for Managing Diabetes Print E-mail
By Staff and Wire Reports   
Tuesday, 10 July 2012 19:52
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 10, 2012

Pernix Therapeutics (NYSE: PTX)
announced Omeclamox-Pak® is now available to patients for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients. Omeclamox-Pak is a ten-day, triple combination oral therapy comprised of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg).


=====


More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott (NYSE: ABT) announced today CE Marking (Conformite Europeenne) for the Abbott ARCHITECT HbA1c (IA) Assay.

Glycated hemoglobin, also known as HbA1c, is a form of hemoglobin used primarily to monitor long-term diabetes control. This helps physicians understand how well the patient's diabetes is being managed from a treatment or dosing perspective. The HbA1c test differs from a patient-administered blood glucose test, which takes a snapshot of a patient's blood sugar level at a moment in time. The HbA1c test must be performed on a laboratory instrument.



Also Tuesday:




Bacterin International Holdings, Inc. (NYSE Amex: BONE)
, a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, announces its fourth national GPO (group purchasing organization) contract, a three-year agreement with the Premier healthcare alliance, one of the nations largest GPOs, serving over 2,600 hospitals and more than 84,000 other healthcare sites that represent over $43 billion in annual purchasing power.

Biodel Inc. (Nasdaq: BIOD)
announced today that management will be presenting an overview of the Company's technologies, development programs, and outlook on Friday, July 13, 2012 at 11:30 a.m. EDT at the Seventh Annual JMP Securities Healthcare Conference (New York, July 12 - 13).

Exelixis, Inc. (NASDAQ:EXEL)
announced today that Charles Butler, the company’s vice president of investor relations and corporate communications, will present at the JMP Securities 7th Annual Healthcare Conference at 9:30 a.m. EDT / 6:30 a.m. PDT on Friday, July 13, 2012, in New York.

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK)
today reported results for the fourth quarter and year ended April 30, 2012.

Human Genome Sciences, Inc. (Nasdaq: HGSI)
announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for raxibacumab, a treatment for inhalational anthrax, and has established December 15, 2012 as the Prescription Drug User Fee Act (PDUFA) action date.

ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC)
, a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license.

Ingen Technologies, Inc. (PINKSHEETS: IGNT)
, an emerging medical device manufacturer with proprietary products for the growing $4B respiratory markets, announced today that the company is moving forward with a leading national medical supplier for the home healthcare and hospital markets.

InVivo Therapeutics Holdings Corp. (NVIV)
, a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that Frank Reynolds, InVivo Therapeutics Chief Executive Officer, will present at the OneMedForum Conference at 1:30 pm EST on July 12th in New York City at the Metropolitan Club in the Morton Room.

InSite Vision Incorporated (OTCBB:INSV)
today announced that Chief Executive Officer Timothy Ruane will speak at the 7th Annual JMP Securities Healthcare Conference on Thursday, July 12, 2012 at 10:30 am Eastern at the Peninsula Hotel New York in New York, NY.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX)
today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 7th Annual JMP Securities Healthcare Conference, being held July 12-13, 2012, in New York City.

MetaStat, Inc. (OTCBB: MTST)
announced today that it has received notice of allowance from the U.S. Patent Office for U.S. Patent Application No. 11/659,514 and notice of allowance of European Patent Application no. 05807467.5.

Nektar Therapeutics (Nasdaq: NKTR)
today announced the private placement of $125 million of 12.0% Senior Secured Notes Due in 2017 in an offering exempt from the registration requirements of the Securities Act of 1933.

Ohr Pharmaceutical (OTCBB: OHRP)
today announced positive results from a long term safety study of Squalamine eye drops being developed for the treatment of the wet form of age-related macular degeneration ("wet-AMD") and other ophthalmic neovascular disorders.

PROLOR Biotech, Inc. (NYSE MKT: PBTH)
, announced that the company will present data today on its long-acting clotting factors for the treatment of hemophilia at the World Federation of Hemophilia (WFH) World Congress.

Synageva BioPharma Corp. (NASDAQ:GEVA)
, a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 2,428,000 shares at $41.20 per share.

TherapeuticsMD™, Inc. (OTCQB: TXMD)
, parent company of vitaMedMD®, LLC (“vitaMedMD”), a specialty pharmaceutical company (“TherapeuticsMD” or the “Company”), announced today its plans to file up to three Investigational New Drug applications (“INDs”) with the U.S. Food and Drug Administration (“FDA”) this year and if accepted, will initiate Phase III clinical trials in the field of hormone therapy for menopausal women.

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA)
, a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the second quarter of 2012 on Thursday, August 2, 2012, before the market opens.

VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (OTCQX:VPTDF)
has installed its VMS™ heart analysis system at the Baylor Heart Clinic at Baylor College of Medicine (BCM) in Houston. Physicians at BCM will use the device to support VentriPoint's clinical trials program and for other research purposes.

WaferGen Bio-systems, Inc. (OTCBB: WGBS)
announced today the commercial launch of MyDesign – an open format product offering for its SmartChip System.  

Zalicus Inc. (NASDAQ: ZLCS)
, a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it is has initiated a Phase 1 multiple ascending dose (MAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter